What Multus Biotechnology does
Multus Biotechnology Ltd designs cell culture media, the nutrient solutions in which cells grow. Its tagline is better media, by design, and its address is the Translation and Innovation Hub on Wood Lane in London. The company says it partners with industry leaders in therapeutics, food and advanced materials, and its pages group projects across four sectors.
Media matter in cultivated meat because the growth medium is one of the largest cost items in producing cells at scale. The company’s food-related offer therefore appears under cellular agriculture. Readers who want the sector background can use the page on cultivated meat, which explains how cells are expanded in bioreactors and where medium enters the cost.
Multus works as a service and formulation company, not as a seller of one catalogue medium. It designs a formulation against the customer’s cells, goals and ingredient constraints, then hands over the recipe with a technical package and a route to supply. Media suppliers who use its capacity keep recipes and supplier relationships confidential.
The MediOP platform
MediOP is the company’s design platform. The pages describe a loop of five steps: design, automate, culture, read and learn. An algorithm proposes candidate formulations, robots prepare them in parallel, cells are grown in every condition at once, automated analytics read the results, and machine learning decides what to test next. The company cites about 600 formulations per cycle.
The site gives figures for scale: up to 86 interacting ingredients per formulation, 865 or more conditions run in parallel, roughly 200,000 data points per iteration, and a claim of five times faster progress from first design to a transferable formulation. The home page cites a vast space of possible formulations, which explains the need for a search algorithm.
At project close, the company arranges quality control testing, batch documentation and supplier qualification so that the formulation can move to production. The portfolio page states timelines of 1 to 3 months for focused optimisation and 6 to 9 months for full de novo development. It lists five delivered projects and two in progress, with six cell types worked on.
Media for cellular agriculture
Three formulations on the portfolio page are relevant to food. Proliferum P is a proliferation medium for porcine adipose-derived stem cells, animal-component-free and chemically defined, with a specification sheet. Proliferum B is listed as delivered. Food Grade DMEM/F12 is a basal medium made in an FSSC 22000 certified facility and validated on bovine and murine muscle cells.
Animal-component-free media avoid serum from animals, and chemically defined media list every component, which helps batch consistency and regulatory documentation for a novel food dossier. The company claims its food-grade formulations can cut formulation cost by up to 90 percent, a figure a buyer should test against current media in a head-to-head experiment.
The page notes that these formulations were developed in-house, so no partner data is used in them, and that samples can be requested through its contact page. Other projects concern cell and gene therapy and antibody production, so food teams should confirm that their project will receive a dedicated design effort.
Applications beyond food
The portfolio also lists serum-free stem cell media and chemically defined media for umbilical cord mesenchymal stem cells, both aimed at cell and gene therapy. Two projects in progress cover cell and gene therapy and antibody production. The company says biopharma developers and contract manufacturers can use process-specific media and feeds aimed at higher yield and batch consistency.
The mix of therapeutic and food projects is relevant for a food buyer. Pharmaceutical customers typically require extensive documentation, and a supplier used to those standards can supply quality records that regulators of novel foods also request. The home page cites statistics about biomedical research and regulatory rejections linked to media, which show where the company expects demand.
A buyer should ask how capacity is allocated between sectors and whether food projects get access to the same platform as therapeutic ones. The pages name no customers, so references should be requested directly, together with any published or confidential case studies that show a medium moving from design to a production run.
How a buyer would evaluate Multus Biotechnology
Start with the cell line and the goal. Define the species, cell type, target density, cost per litre or per kilogram of cells, and any ingredient constraints, such as food-grade or animal-free status. Ask the company to describe how it would scope the project, how many cycles it expects and what data will be delivered.
Then test the product. Request samples of Proliferum or Food Grade DMEM/F12, and compare them with the current medium on growth rate, viability, differentiation and cost. Ask for the specification sheet, certificate of analysis and the FSSC 22000 certificate, and check which entity holds the certification and which products it covers.
Finally, check supply and ownership. A designed medium has many components, so ask which are single-source, how the company qualifies suppliers and what happens if one fails. Clarify ownership of the formulation, license terms and whether the buyer may transfer production to another media supplier after handover, and who holds the quality records.